Hunan Jiudian Pharmaceutical Co., Ltd.

Shenzhen Stock Exchange 300705.SZ

Hunan Jiudian Pharmaceutical Co., Ltd. Revenue for the year ending December 31, 2023: USD 379.24 M

Hunan Jiudian Pharmaceutical Co., Ltd. Revenue is USD 379.24 M for the year ending December 31, 2023, a 12.50% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

Hunan Jiudian Pharmaceutical Co., Ltd. Revenue for the year ending December 31, 2022 was USD 337.09 M, a 31.59% change year over year.
Hunan Jiudian Pharmaceutical Co., Ltd. Revenue for the year ending December 31, 2021 was USD 256.16 M, a 70.94% change year over year.
Hunan Jiudian Pharmaceutical Co., Ltd. Revenue for the year ending December 31, 2020 was USD 149.85 M, a 12.93% change year over year.
Hunan Jiudian Pharmaceutical Co., Ltd. Revenue for the year ending December 31, 2019 was USD 132.70 M, a 13.88% change year over year.

Key data

Date	Revenue	Gross Profit	Operating Income	EBIT

Shenzhen Stock Exchange: 300705.SZ

Hunan Jiudian Pharmaceutical Co., Ltd.

CEO	Mr. Yang Yang
IPO Date	Oct. 10, 2017
Location	China
Headquarters	Building A1, Shibuya Science and Technology Industrial Park
Employees	1,893
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Cleaning Supplies Cosmetics Drugstores & Retail Pharmacies Personal Care

Description

Hunan Jiudian Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in China. The company offers antiallergic, anti-infective, and anti-inflammatory drugs; analgosies and gynecological medication products; digestive system products; chemical and Chinese patent medicines; medical instruments; APIs; and other products. It also provides outsourcing services for tablets, capsules, granules, oral solutions, syrups, etc. Hunan Jiudian Pharmaceutical Co., Ltd. is based in Changsha, China.

Key trends

Past 5 years